School of Law and Social Justice, University of Liverpool, Mulberry Court, Liverpool, UK.
Med Law Rev. 2020 May 1;28(2):401-411. doi: 10.1093/medlaw/fwaa002.
November 2018 saw the prescription of unlicensed medicinal cannabis products being legalised in the UK, accompanied by loud media fanfare. One year on, it seems that access to medicinal cannabis in this country continues to be extremely rare, raising questions about what might be stopping doctors from making use of the legal space to prescribe. This commentary explores some of these questions, outlining the theoretical space for legal prescribing and examining whether the recently announced National Institute for Health and Care Excellence guideline does anything to ease the deadlock.
2018 年 11 月，英国将未经许可的医用大麻制品的处方合法化，媒体对此大肆宣传。一年过去了，该国似乎仍然极难获得医用大麻，这引发了人们的质疑，即是什么因素阻碍了医生利用这一合法空间来开处方。本评论探讨了其中的一些问题，概述了合法处方的理论空间，并审视了最近公布的国家卫生与保健卓越研究所指南是否为打破僵局提供了任何帮助。
